Brainstorm Cell Therapeutics ALS Trial Shows Stem Cell Treatment Inhibits Disease Progression in 87% of Patients

A new ALS treatment utilizing a stem cell infusion protocol performed at Hadassah Medical Organization (HMO) and developed by the US/Israeli biotech company BrainStorm Cell Therapeutics BCLI, has significantly slowed the progression of Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's Disease), announced Ellen Hershkin, National President of Hadassah, the Women's Zionist Organization of America, Inc. (HWZOA). JAMA Neurology published the findings of the Phase 1/2 and Phase 2a ALS Clinical Trials conducted by Dr. Dimitrios Karussis, MD, PhD, Sr. Neurologist, HMO Neurology, in their 1/11/16 issue.  These Clinical Trials, which began in 2011, utilized an innovative adult stem cell self-transplantation treatment involving the harvesting of stem cells from the patient's bone marrow, their culture and enhancement using Brainstorm's patented protocol NurOwn® and See full press release